Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  ImmunoCellular Therapeutics Ltd    

 SummaryChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 4,30 M
EBIT 2017 -19,8 M
Net income 2017 -21,2 M
Debt 2017 -
Yield 2017 -
Sales 2018 4,30 M
EBIT 2018 -20,3 M
Net income 2018 -21,7 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 2,64x
Capi. / Sales2018 2,64x
Capitalization 11,4 M
More Financials
Company
ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers.Its lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. 
More about the company
Latest news on IMMUNOCELLULAR THERAPEUTIC
03/23 IMMUNOCELLULAR THERAPEUTICS : and Memgen Announce Letter of Intent for Potential..
03/16 IMMUNOCELLULAR THERAPEUTICS : Announces Fourth Quarter and Full Year 2016 Financ..
03/14 IMMUNOCELLULAR THERAPEUTICS : Receives Audit Opinion With Going Concern Explanat..
03/09 IMMUNOCELLULAR THERAPEUTICS : Management's Discussion and Analysis of Financial ..
03/09 IMMUNOCELLULAR THERAPEUTICS, LTD. (N : IMUC) Files An 8-K Results of Operations ..
03/09 IMMUNOCELLULAR THERAPEUTICS, LTD. : Results of Operations and Financial Conditio..
03/09 IMMUNOCELLULAR THERAPEUTICS : Announces Fourth Quarter and Full Year 2016 Financ..
03/06 IMMUNOCELLULAR THERAPEUTICS : to Report Fourth Quarter and Full Year 2016 Financ..
03/06 IMMUNOCELLULAR THERAPEUTICS : Provides Update on ICT-107 Phase 3 Glioblastoma Tr..
02/24 IMMUNOCELLULAR THERAPEUTICS : SAVSU Technologies Provides Performance Update on ..
More news
Sector news : Biotechnology & Medical Research - NEC
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
2016 ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q3 2016 Results - Ea..
2016 ImmunoCellular Therapeutics EPS in-line
2016 ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q2 2016 Results - Ea..
2016 ImmunoCellular Therapeutics beats by $0.01
2016 ImmunoCellular's late-stage study of lead product candidate in glioblastoma c..
Advertisement
Chart IMMUNOCELLULAR THERAPEUTIC
Duration : Period :
ImmunoCellular Therapeutic Technical Analysis Chart | US4525361055 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 1
Average target price -
Spread / Average Target -100%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Anthony J. Gringeri President, Chief Executive Officer & Director
Gary S. Titus Chairman & Secretary
David E. Fractor Principal Financial Officer & VP-Finance
John S. Yu Director
Rahul Singhvi Lead Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOCELLULAR THERAPE..797.83%11
INCYTE CORPORATION39.10%28 429
QUINTILES IMS HOLDINGS..3.48%18 567
LONZA GROUP AG3.12%10 618
CELLTRION, INC.--.--%9 982
SEATTLE GENETICS, INC.22.17%9 187
More Results